OncoTriage. Поиск наилучшего лечения для вашего пациента

Цитопении и ПНГ

Медицинские публикации по различного рода цитопениям, апластической анемии и пароксизмальной ночной гемоглобинурии.

Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment.

In patients with paroxysmal nocturnal hemoglobinuria (PNH), complement component 5 (C5) inhibitors ravulizumab and eculizumab control terminal complement activity and intravascular hemolysis, drivers of morbidity and mortality...

DOI: 10.1182/bloodadvances.2024015490

Kulasekararaj AG, Lee JW, Patriquin CJ, Piatek CI, Röth A, Barcellini W, Brodsky RA, Nishimura JI, Yu J, Mahdi M, Peffault De Latour R

Blood advances, 2025-04-26

How we manage immune-mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance.

The use of rituximab, a B-cell-depleting agent as a pre-emptive treatment in immune-mediated thrombotic thrombocytopenic purpura (iTTP), is the current standard of care...

DOI: 10.1111/bjh.20101

Weisinger J, Fadlallah J, Joly B, Veyradier A, Coppo P

British journal of haematology, 2025-04-26

The management of antiplatelet therapy in patients with coronary artery disease and thrombocytopenia.

Ischemic heart disease is the leading cause of death in the world...

DOI: 10.1016/j.amjms.2025.04.007

Velibey Y, Altay S, Bolca O

The American journal of the medical sciences, 2025-04-25

Predictors of progression to chronicity in newly diagnosed primary immune thrombocytopenia: a retrospective multicenter French study.

In this retrospective French cohort, predictors of chronicity in newly diagnosed primary adult ITP included the absence of preceding infectious event, platelet > 10 x 109/L and absence of bleeding manifestations at onset.

DOI: 10.1080/17474086.2025.2495669

Damian L, Langlois V, Jardin F, Kerleau JM, Grall M, Levesque H, Benhamou Y, Sauvetre G

Expert review of hematology, 2025-04-25

Risk factors for thrombocytopenia associated with intravenous valproic acid therapy in pediatric patients undergoing neurosurgical operations.

Thrombocytopenia is one of the side effects of VPA...

DOI: 10.1038/s41598-025-98870-8

Du Z, Wang J, Nie G, Li Y, Liu M

Scientific reports, 2025-04-23

T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy.

Immune effector cell-associated hematotoxicity (ICAHT) was recently introduced as a distinct toxicity category of CAR-T therapy...

DOI: 10.1182/blood.2025028833

Rejeski K, Sanz J, Fei T, Nair MS, Hashmi H, Avigdor A, Beyar-Katz O, Bücklein VL, Curran KJ, Einarsdottir S, Esensten JH, Glaubach N, Golan-Accav N, Gomez-Llobell M, Halamis I, Itzhaki O, Locke FL, Mailankody S, Marcus R, Maus MV, Palomba ML, Park J

Blood, 2025-04-23

Efficacy and safety of dapsone in adult primary immune thrombocytopenia.

To assess efficacy and safety of dapsone in adult immune thrombocytopenia (ITP), a multicenter randomized controlled trial (RCT) and a real-world cohort study were performed...

DOI: 10.1182/bloodadvances.2024014939

Larue M, Moulis G, Rueter M, Audia S, Comont T, Terriou L, Viallard JF, Pan-Petesch B, Royer B, Bonnotte B, Galicier L, Lambotte O, Lefrere F, Cheze S, Ebbo M, Duong TA, Boutin E, Languille L, Mahevas M, Godeau B, Canoui-Poitrine F, Michel M

Blood advances, 2025-04-25

Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies.

Iptacopan, a first-in-class, oral, selective complement factor B inhibitor, demonstrated efficacy and safety as monotherapy in C5 inhibitor (C5i)-experienced (APPLY-PNH; NCT04558918) and C5i-naive (APPOINT-PNH; NCT04820530) patients with paroxysmal nocturnal hemoglobinuria (PNH)...

DOI: 10.1182/bloodadvances.2024014652

Risitano AM, de Castro C, Han B, Kulasekararaj A, Maciejewski JP, Scheinberg P, Ueda Y, Vallow S, Bermann G, Dahlke M, Kumar R, Peffault de Latour R

Blood advances, 2025-04-24

Наверх